PDUFA V and Investor Communications
This article was originally published in RPM Report
Executive Summary
The Prescription Drug User Fee Act reauthorization made a number of important changes to the new drug review process and programs for stakeholder engagement with FDA. It also created a number of new investor communication challenges for sponsors.